MetLife shares continue to outpace the broader market, climbing 22.5% year-to-date as the company leverages strong underwriting growth and consistent revenue streams to outperform rivals like Aflac.
MetLife has demonstrated significant strength, outperforming the Nasdaq with a 17% gain over three months and a 32.6% return over the past year. This momentum is supported by strong Q2 2026 earnings, where adjusted EPS rose 20.3%, and a consensus 'Moderate Buy' rating from analysts.
Analysts maintain a 'Moderate Buy' rating with a mean price target of $106.23, representing an 8.8% upside.
Revenue growth was driven by favorable underwriting and volume growth, resulting in a 7% increase to $13.7 billion.
MetLife (MET) continues to demonstrate strong market resilience, posting a 17% gain over the last three months while the Nasdaq Composite slipped 1.2%. Driven by a 20.3% increase in adjusted earnings per share, the insurer maintains a Moderate Buy rating from analysts who project an 8.8% upside potential from current levels.
Over the past three months, MetLife has climbed 17%, while the Nasdaq Composite declined 1.2%.
Analysts hold a consensus Moderate Buy rating on MET, with a mean price target of $106.23, suggesting an 8.8% upside.